A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1005 | Th1002 | Cetuximab | Heavy chain:QVQLKQSG Full view | 243 | IIIc | Cancer | Erbitux | ImClone Systems Inc | Sterile, clear, colorless liquid of pH 7.0-7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates | Intravenous infusion | Antineoplastic Agents | Epidermal growth factor receptor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1548 | Th1117 | Ipilimumab | Heavy chain: QVQLVES Full view | 663 | IIIc | Cancer | YERVOY | Bristol-Myers Squibb | Sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution | N.A. | Antineoplastic Agents and Monoclonal antibodies | Cytotoxic T-lymphocyte protein 4 |
| 1549 | Th1118 | Sulodexide | N.A. Full view | 0 | IIIc | Hormonal/genetic/Hematological/N.A. | SULODEXIDE | Syntex S.A | N.A. | N.A. | Antithrombins and Fibrinolytic Agents and Hypoglycemic Agents and Anticoagulants and Hypolipidemic Agents | Heparin cofactor 2,Antithrombin-III |
| 1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
| 1570 | Th1123 | Denosumab | Heavy chain EVQLLESG Full view | 664 | IIIc | Osteological | Xgeva | Amgen. | Sterile, preservative-free, clear, colorless to pale yellow solution | N.A. | Bone Density Conservation Agents and Monoclonal antibodies | Tumor necrosis factor ligand superfamily member 11 |
| 1571 | Th1123 | Denosumab | Heavy chain EVQLLESG Full view | 664 | IIIc | Osteological | Prolia | Amgen. | Sterile, preservative-free, clear, colorless to pale yellow solution | N.A. | Bone Density Conservation Agents and Monoclonal antibodies | Tumor necrosis factor ligand superfamily member 11 |
| 1600 | Th1127 | Buserelin | N.A. Full view | 0 | IIIc | Cancer/Hormonal | Suprecur (Nasal Spray Solution) | Sanofi-Aventis | 150 micrograms Nasal Spray Solution | Nasal spray | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1601 | Th1127 | Buserelin | pGlu-His-Trp-Ser-Tyr Full view | 9 | IIIc | Cancer/Hormonal | Suprecur (injection) | Sanofi-Aventis | 1mg/ml Injection | Subcutaneous injection | N.A. | Lutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
| 1664 | Th1156 | Abarelix | N.A. Full view | 0 | IIIc | Hormonal | Plenaxis | Speciality european pharma | White to off-white sterile dry powder | Intramuscular Injection | Anti-Testosterone Agents | Gonadotropin-releasing hormone receptor |
| 1708 | Th1170 | Blinatumomab | DIQLTQSPASLAVSLGQRAT Full view | 504 | IIIc | Cancer/Genetic | Blincyto | AMGEN | Lyophilized Powder for intravenous administration | Intravenous | Antineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents | B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain |
| 1724 | Th1174 | Daratumumab | NA Full view | 0 | IIIc | Cancer | Darzalex | Janssen Biotech, Inc. | Solution, concentrate | Intravenous | Antineoplastic Agents | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
| 1738 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | NA | NA | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | SLAM family member 7 |
| 1739 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 8 |
| 1740 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 9 |
| 1753 | Th1181 | Filgrastim-sndz | NA Full view | 0 | IIIc | Cancer | Zarxio | Sandoz Inc | Solution | Intravenous; Subcutaneous | NA | NA |
| 1805 | Th1199 | Ramucirumab | ramucirumab|Homo sap Full view | 909 | IIIc | Cancer | Cyramza | Eli Lilly and Company | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Vascular endothelial growth factor receptor 2 |
| 1811 | Th1202 | Pembrolizumab | Heavy Chain Sequence Full view | 711 | IIIc | Cancer | Keytruda | Merck Sharp & Dohme Corp. | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1813 | Th1204 | Ofatumumab | Ofatumumab Heavy Cha Full view | 483 | IIIc | Cancer | Arzerra | Glaxo Smith Kline Llc | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | |
| 1815 | Th1206 | Nivolumab | Heavy Chain Sequence Full view | 710 | IIIc | Cancer | Opdivo | E.R. Squibb & Sons, L.L.C. | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1816 | Th1207 | Necitumumab | NA Full view | 0 | IIIc | Cancer | Portrazza | Eli Lilly and Company | Sterile, preservative free, clear to slightly opalescent and colorless to slightly yellow Solution | Intravenous | NA | NA |
| 1837 | Th1226 | Dinutuximab | NA Full view | 0 | IIIc | Cancer | unituxin | NA | sterile, preservative-free, clear/colorless to slightly opalescent solution | Intravenous | Antibody, Immunosuppresive agent, Antineoplastic agent | Ganglioside GD2 (small molecule) |
| 1843 | Th1231 | Ibritumomab tiuxetan | Heavy chain: QAYLQQS Full view | 652 | IIIc | Cancer | Zevalin | Spectrum Pharmaceuticals B.V. | Colourless Solution | Intravenous | Antibody, Immunosuppressive Agents | B-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1848 | Th1236 | Sipuleucel-T | NA Full view | 0 | IIIc | Cancer | Provenge | NA | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Prostatic acid phosphatase |